We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals

130 hedge funds and large institutions have $1.49B invested in Xenon Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 49 increasing their positions, 29 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

278% more capital inflows, than outflows

Capital inflows: $538M | Capital outflows: $142M

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

69% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 29

31% more call options, than puts

Call options by funds: $6.15M | Put options by funds: $4.7M

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

10% more funds holding

Funds holding: 118 → 130 (+12)

9.51% more ownership

Funds ownership: 82.93% → 92.44% (+9.5%)

Holders
130
Holders Change
+12
Holders Change %
+10.17%
% of All Funds
1.99%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
31
Increased
49
Reduced
29
Closed
24
Calls
$6.15​M
Puts
$4.7​M
Net Calls
+$1.44​M
Net Calls Change
-⁠$6.62​M

XENE Hedge Fund Activity: Q4 2021 in Review

130 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2021, worth a combined $1.49B — up 186% from $522M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new XENE positions and 24 closed out — a net gain of 7 holders — while 49 added to existing stakes and 29 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $57.2M. The largest seller was Ghost Tree Capital, cutting an estimated $20.6M.

  • 130 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2021, up from 118 in Q3 2021.
  • Funds reported $1.49B of Xenon Pharmaceuticals stock for Q4 2021, up 186% quarter-over-quarter.
  • 31 funds opened new Xenon Pharmaceuticals positions in Q4 2021 and 24 closed out, a net change of +7 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2021 was Point72 Asset Management, an estimated $57.2M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2021 was Ghost Tree Capital, an estimated $20.6M sold.

Based on aggregated 13F filings for Q4 2021.